MAPT and tauopathy: TRx0237, a drug entering clinical phase III trial with known pharmacological and toxicological profiles, may represent a promising therapy for various GCs-associated adverse effects, particularly GIO, p-Tau Ser422-associated tauopathy and other pathological conditions, such as acute stress, in which GCs are markedly stimulated.69